Telesair
An Innovator of Next-Gen Respiratory Care Solutions

Among the various kinds of respiratory diseases that negatively impact people across nation, chronic obstructive pulmonary disease (COPD) affects over 15 million Americans, decreasing their quality of life significantly. The pandemic further exacerbated the situation for patients and their doctors as well, where procuring and managing necessary medical resources and equipment became a very pressing challenge. The demand for respiratory devices is at an all-time high. Additionally, complexity involved in the usage of such devices is another problem affecting both caregivers and patients in home and hospital settings. A more streamlined technology, such as machine automation, will make respiratory devices more user friendly in the context of home care and render more safety to professionals who operate the machines.

Telesair, Inc., a California-based new technology development startup, recognized this growing impediment and seeks to innovate tech-based respiratory devices for improved safety and efficacy in oxygen generation, conditioning, and delivery for the medical industry at large.

“Our goal is to develop respiratory care solutions for patients suffering from respiratory ailments and get them out of the hospital and into the home sooner than expected,” says Bryan Liu, Founder and CEO at Telesair. The company has patented several respiratory care inventions and utilizes the innovative technologies to design and manufacture a new generation of devices.

Telesair is creating intelligent respiratory care solutions using real clinical data, advanced engineering design processes, and IoT technologies to provide compact, ease of use, and mobile respiratory care solutions to hospitals, long-term care and skilled nursing facilities, and in the home care setting. For instance, all current respiratory devices require caregivers to be with the devices to adjust therapy. It takes precious time from caregivers to walk from patient to patient and expose them to infection risk.

Consequently, caregivers are exposed to risks of being infected and have less time to care patients, which further reduces the number of caregivers, resulting patients not receiving much needed care. Telesair’s patented remote monitor and remote control respiratory devices can be a game changer, all while reducing the workload on the respiratory therapists and the nurses to significantly and help circumvent the challenges of personnel shortages and protect caregivers at the same time. Above all, Telesair is set to benefit patients and caregivers and increase efficiency for patient care.

The company’s remote respiratory devices are manufactured to effectuate safer management of patients both in hospitals and at home. It would put less risk on the respiratory therapist as close contact with patients could be minimized.

To further improve the scope of respiratory devices, Telesair will be introducing its first nasal high flow device later this year, featuring a 33 percent higher flow rate, large forward-facing touchscreen, and 95% faster disinfection process. Future upgrades to the device will focus on IoT technologies enabled through the company’s remote control functionality, and further enhanced with the ability to perform closed-loop automation through proprietary algorithms, designed to speed up respiratory care processes while improving operational efficiencies. Telesair’s innovative remote-control solution can enable patients to be more involved in their care by making them active participants in controlling their comfort settings using the remote.

Such innovations not only reduce the financial burden on both the healthcare system and patients but also allow medical professionals to concentrate on more pressing needs. Telesair’s devices are capable of addressing the currently soaring demand for respiratory devices and improving the overall healthcare experience for all parties. Supported by excellent research and development teams in the respiratory solution space, Telesair will continue to develop its pipeline of proprietary solutions to address a wide array of respiratory diseases.